Logo

American Heart Association

  32
  0


Final ID: MP1494

Not All LDLs are Created Equal: Discordance Between Calculated LDL-C Estimates and Incident ASCVD in the Multi-Ethnic Study of Atherosclerosis

Abstract Body (Do not enter title and authors here): Introduction: The Friedewald equation (F-LDL-C) is the most widely used estimate of LDL-cholesterol (LDL-C), but it can be inaccurate at high TG and low LDL-C. The Martin-Hopkins (MH-LDL-C) and the Sampson (S-LDL-C) equations more accurately estimate LDL-C. Individuals with discordant LDL-C estimates may be undertreated for their ASCVD risk, depending on the equation used. The association of discordance in LDL-C estimates with ASCVD risk is not well established.
Hypothesis: Individuals with greater discordance in LDL-C estimates are at higher risk for incident ASCVD
Methods: We estimated F-LDL-C, MH-LDL-C, and S-LDL-C in 6636 patients (mean 61.6 years, 47% male) with TG < 400 mg/dL in the Multi-Ethnic Study of Atherosclerosis. We divided the cohort into quintiles (Q1-Q5) of LDL-C discordance, measured by the absolute difference of LDL-C values between equations (MH-LDL-C minus F-LDL-C, S-LDL-C minus F-LDL-C, MH-LDL-C minus S-LDL-C). We examined the association of characteristics (sex, age, race, BMI, diabetes, hypertension, tobacco use) with quintile of discordance using the Jonckheere-Terpstra test. We used multivariable adjusted Cox regression models to assess the hazard associated with quintiles of discordance for ASCVD events (MI, stroke, CV death, or revascularizations).
Results: Greater LDL-C discordance (when MH-LDL-C and S-LDL-C were higher than F-LDL-C) was significantly associated with male sex, higher BMI, diabetes, hypertension, and tobacco use in unadjusted models. There were 1,275 ASCVD events over a median follow up of 18.4 years. The distribution of intra-quintile LDL-C values grew exponentially in Q5 across all groups, with the MH – F cohort demonstrating the greatest LDL-C range (absolute difference of 31.2 mg/dL). In fully adjusted Cox models, those in Q4 (HR 1.23, 95% CI 1.03-1.48) and Q5 (HR 1.28, 95% CI 1.06-1.55) of LDL-C discordance (where MH-LDL-C was higher than F-LDL-C) had a higher hazard for ASCVD events. Greater discordance between S-LDL-C and F-LDL-C trended towards increased ASCVD risk, but the results were not statistically significant.
Conclusions: Greater LDL-C discordance where MH-LDL-C was higher than F-LDL-C is independently associated with greater ASCVD, after adjustments for variables associated with higher discordance. Our findings favor using newer equations to estimate LDL-C and suggest that this high-risk group is at risk for being undertreated if targeting the widely used F-LDL-C estimates.
  • Canga, Sophia  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Quispe, Renato  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Muthukumar, Alagarraju  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Joshi, Parag  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Macpherson, Nicholas  ( Connected Cardiovascular Care , Dallas , Texas , United States )
  • Vasquez, Nestor  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Khera, Amit  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Rohatgi, Anand  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Martin, Seth  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Jones, Steven  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Ayers, Colby  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Navar, Ann Marie  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Author Disclosures:
    Sophia Canga: DO NOT have relevant financial relationships | Renato Quispe: No Answer | Alagarraju Muthukumar: DO NOT have relevant financial relationships | Parag Joshi: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Consultant:New Amsterdam Pharma:Past (completed) ; Consultant:Kaneka:Past (completed) ; Consultant:Novartis:Past (completed) ; Research Funding (PI or named investigator):Kaneka:Past (completed) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) | Nicholas Macpherson: No Answer | Nestor Vasquez: No Answer | Amit Khera: DO NOT have relevant financial relationships | Anand Rohatgi: DO have relevant financial relationships ; Consultant:Raydel:Past (completed) ; Consultant:JP Morgan:Past (completed) ; Consultant:Johnson and Johnson:Past (completed) ; Other (please indicate in the box next to the company name):LabCorp:Active (exists now) ; Other (please indicate in the box next to the company name):Quest:Active (exists now) ; Research Funding (PI or named investigator):CSL Behring:Past (completed) | Seth Martin: DO have relevant financial relationships ; Consultant:Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Care Access, Chroma, Bristol Myers Squibb, Heartflow, Kaneka, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk, Premier, Sanofi, Verve Therapeutics, :Past (completed) ; Ownership Interest:Corrie Health, Prevent Medical:Active (exists now) ; Other (please indicate in the box next to the company name):American Heart Association (Immediate Past Chair, EPI Statistics Committee):Active (exists now) ; Other (please indicate in the box next to the company name):National Lipid Association (SELA President):Active (exists now) ; Other (please indicate in the box next to the company name):Editorial Board Member (AJPC, EJPC, JCL):Active (exists now) ; Research Funding (PI or named investigator):National Institutes of Health, Patient-Centered Outcomes Research Institute, American Heart Association, American College of Cardiology:Active (exists now) ; Employee:Johns Hopkins School of Medicine :Active (exists now) ; Other (please indicate in the box next to the company name):National Institutes of Health Data Safety and Monitoring Board:Active (exists now) | Steven Jones: DO NOT have relevant financial relationships | Colby Ayers: DO have relevant financial relationships ; Consultant:NIH:Active (exists now) | Ann Marie Navar: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Amgen, Arrowhead, Bayer, Esperion, Janssen, Eli Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Roche, Silence Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Esperion:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Cholesterol Chronicles: Lipid Markers and Cardiovascular Disease

Sunday, 11/09/2025 , 11:50AM - 01:05PM

Moderated Digital Poster Session

More abstracts on this topic:
Access to Lipid-Lowering Therapies is Limited by Payer Coverage Restrictions and High Out-of-Pocket Costs on Medicare Prescription Drug Plans

Young Grant, Bansal Kannu, Riello Ralph, Faridi Kamil, Clark Katherine, Desai Nihar

Abdominal Aortic Perivascular Adipose Tissue Lipolysis Is Activated In Hypertensive Dahl SS Rats Fed a High-Fat Diet

Chirivi Miguel, Rendon Javier, Lauver Adam, Fink Gregory, Watts Stephanie, Contreras Andres

More abstracts from these authors:
Physician-Level Variation in Lipid Management for Secondary Prevention of Atherosclerotic Cardiovascular Disease: Opportunities for Practice Improvement

Nguyen Danh, Hwang Jimin, Peterson Eric, Rohatgi Anand, Joshi Parag, Khera Amit, Navar Ann Marie

Need for Testing Standardization and Improved Treatment of Elevated Lipoprotein(a) at a Large Urban Academic Medical Center

Wong Willis, Kao Cindy Hsin-yi, Schneider Ruth, Navar Ann Marie, Rohatgi Anand, Khera Amit, Joshi Parag

You have to be authorized to contact abstract author. Please, Login
Not Available